1
|
Scialla S, Genicio N, Brito B, Florek-Wojciechowska M, Stasiuk GJ, Kruk D, Bañobre-López M, Gallo J. Insights into the Effect of Magnetic Confinement on the Performance of Magnetic Nanocomposites in Magnetic Hyperthermia and Magnetic Resonance Imaging. ACS APPLIED NANO MATERIALS 2022; 5:16462-16474. [PMID: 36569339 PMCID: PMC9778729 DOI: 10.1021/acsanm.2c03537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 09/27/2022] [Indexed: 06/17/2023]
Abstract
The combination of superparamagnetic iron oxide nanoparticles (SPIONs) and lipid matrices enables the integration of imaging, drug delivery, and therapy functionalities into smart theranostic nanocomposites. SPION confinement creates new interactions primarily among the embedded SPIONs and then between the nanocomposites and the surroundings. Understanding the parameters that rule these interactions in real interacting (nano)systems still represents a challenge, making it difficult to predict or even explain the final (magnetic) behavior of such systems. Herein, a systematic study focused on the performance of a magnetic nanocomposite as a magnetic resonance imaging (MRI) contrast agent and magnetic hyperthermia (MH) effector is presented. The effect of stabilizing agents and magnetic loading on the final physicochemical and, more importantly, functional properties (i.e., blocking temperature, specific absorption rate, relaxivity) was studied in detail.
Collapse
Affiliation(s)
- Stefania Scialla
- Advanced
(Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330Braga, Portugal
| | - Nuria Genicio
- Advanced
(Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330Braga, Portugal
| | - Beatriz Brito
- Advanced
(Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330Braga, Portugal
- Department
of Imaging Chemistry and Biology, School of Biomedical Engineering
and Imaging Sciences, King’s College
London, Strand, LondonSE1 7EH, U.K.
- School
of Life Sciences, Faculty of Health Sciences, University of Hull, Cottingham Road, HullHU6 7RX, U.K.
| | - Malgorzata Florek-Wojciechowska
- Department
of Physics and Biophysics, Faculty of Food Science, University of Warmia & Mazury in Olsztyn, Oczapowskiego 4, 10-719Olsztyn, Poland
| | - Graeme J. Stasiuk
- Department
of Imaging Chemistry and Biology, School of Biomedical Engineering
and Imaging Sciences, King’s College
London, Strand, LondonSE1 7EH, U.K.
| | - Danuta Kruk
- Department
of Physics and Biophysics, Faculty of Food Science, University of Warmia & Mazury in Olsztyn, Oczapowskiego 4, 10-719Olsztyn, Poland
| | - Manuel Bañobre-López
- Advanced
(Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330Braga, Portugal
| | - Juan Gallo
- Advanced
(Magnetic) Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330Braga, Portugal
| |
Collapse
|
2
|
Cerqueira M, Belmonte-Reche E, Gallo J, Baltazar F, Bañobre-López M. Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics. Pharmaceutics 2022; 14:pharmaceutics14030506. [PMID: 35335882 PMCID: PMC8950239 DOI: 10.3390/pharmaceutics14030506] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 02/20/2022] [Accepted: 02/22/2022] [Indexed: 02/01/2023] Open
Abstract
Cancer is currently a leading cause of death worldwide. The World Health Organization estimates an increase of 60% in the global cancer incidence in the next two decades. The inefficiency of the currently available therapies has prompted an urgent effort to develop new strategies that enable early diagnosis and improve response to treatment. Nanomedicine formulations can improve the pharmacokinetics and pharmacodynamics of conventional therapies and result in optimized cancer treatments. In particular, theranostic formulations aim at addressing the high heterogeneity of tumors and metastases by integrating imaging properties that enable a non-invasive and quantitative assessment of tumor targeting efficiency, drug delivery, and eventually the monitoring of the response to treatment. However, in order to exploit their full potential, the promising results observed in preclinical stages need to achieve clinical translation. Despite the significant number of available functionalization strategies, targeting efficiency is currently one of the major limitations of advanced nanomedicines in the oncology area, highlighting the need for more efficient nanoformulation designs that provide them with selectivity for precise cancer types and tumoral tissue. Under this current need, this review provides an overview of the strategies currently applied in the cancer theranostics field using magnetic nanoparticles (MNPs) and solid lipid nanoparticles (SLNs), where both nanocarriers have recently entered the clinical trials stage. The integration of these formulations into magnetic solid lipid nanoparticles—with different composition and phenotypic activity—constitutes a new generation of theranostic nanomedicines with great potential for the selective, controlled, and safe delivery of chemotherapy.
Collapse
Affiliation(s)
- Mónica Cerqueira
- Life and Health Sciences Research Institute (ICVS), Campus of Gualtar, University of Minho, 4710-057 Braga, Portugal;
- ICVS/3B’s—PT Government Associate Laboratory, 4805-017 Guimarães, Portugal
- Advanced (Magnetic) Theranostic Nanostructures Lab, Nanomedicine Unit, International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, 4715-330 Braga, Portugal; (E.B.-R.); (J.G.)
| | - Efres Belmonte-Reche
- Advanced (Magnetic) Theranostic Nanostructures Lab, Nanomedicine Unit, International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, 4715-330 Braga, Portugal; (E.B.-R.); (J.G.)
| | - Juan Gallo
- Advanced (Magnetic) Theranostic Nanostructures Lab, Nanomedicine Unit, International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, 4715-330 Braga, Portugal; (E.B.-R.); (J.G.)
| | - Fátima Baltazar
- Life and Health Sciences Research Institute (ICVS), Campus of Gualtar, University of Minho, 4710-057 Braga, Portugal;
- ICVS/3B’s—PT Government Associate Laboratory, 4805-017 Guimarães, Portugal
- Correspondence: (F.B.); (M.B.-L.)
| | - Manuel Bañobre-López
- Advanced (Magnetic) Theranostic Nanostructures Lab, Nanomedicine Unit, International Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga, 4715-330 Braga, Portugal; (E.B.-R.); (J.G.)
- Correspondence: (F.B.); (M.B.-L.)
| |
Collapse
|
3
|
PLGA-Based Composites for Various Biomedical Applications. Int J Mol Sci 2022; 23:ijms23042034. [PMID: 35216149 PMCID: PMC8876940 DOI: 10.3390/ijms23042034] [Citation(s) in RCA: 88] [Impact Index Per Article: 44.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/07/2022] [Accepted: 02/08/2022] [Indexed: 12/12/2022] Open
Abstract
Polymeric materials have been extensively explored in the field of nanomedicine; within them, poly lactic-co-glycolic acid (PLGA) holds a prominent position in micro- and nanotechnology due to its biocompatibility and controllable biodegradability. In this review we focus on the combination of PLGA with different inorganic nanomaterials in the form of nanocomposites to overcome the polymer’s limitations and extend its field of applications. We discuss their physicochemical properties and a variety of well-established synthesis methods for the preparation of different PLGA-based materials. Recent progress in the design and biomedical applications of PLGA-based materials are thoroughly discussed to provide a framework for future research.
Collapse
|
4
|
García-Hevia L, Casafont Í, Oliveira J, Terán N, Fanarraga ML, Gallo J, Bañobre-López M. Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics. Bioact Mater 2022; 8:153-164. [PMID: 34541393 PMCID: PMC8424388 DOI: 10.1016/j.bioactmat.2021.06.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 05/20/2021] [Accepted: 06/07/2021] [Indexed: 01/13/2023] Open
Abstract
Nowadays, a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations. Thus, the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications. Herein, a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient, green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug (doxorubicin) into a natural nano-matrix. The theranostic performance of the final magnetic formulation was validated in vitro and in vivo, in melanoma tumors. The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy, together with MRI reporting capability. The application of an alternating magnetic field was found to play a dual role, (i) acting as an extra layer of control (remote, on-demand) over the chemotherapy release and (ii) inducing a local thermal ablation of tumor cells. This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes, which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.
Collapse
Affiliation(s)
- Lorena García-Hevia
- Advanced (Magnetic) Theranostic Nanostructures Lab. International Iberian Nanotechnology Laboratory, Avda. Mestre José Veiga s/n, 4715-330, Braga, Portugal
| | - Íñigo Casafont
- Grupo de Nanomedicina. Universidad de Cantabria-IDIVAL, Herrera Oria s/n, 39011, Santander, Spain
| | - Jessica Oliveira
- Advanced (Magnetic) Theranostic Nanostructures Lab. International Iberian Nanotechnology Laboratory, Avda. Mestre José Veiga s/n, 4715-330, Braga, Portugal
| | - Nuria Terán
- Grupo de Nanomedicina. Universidad de Cantabria-IDIVAL, Herrera Oria s/n, 39011, Santander, Spain
| | - Mónica L. Fanarraga
- Grupo de Nanomedicina. Universidad de Cantabria-IDIVAL, Herrera Oria s/n, 39011, Santander, Spain
| | - Juan Gallo
- Advanced (Magnetic) Theranostic Nanostructures Lab. International Iberian Nanotechnology Laboratory, Avda. Mestre José Veiga s/n, 4715-330, Braga, Portugal
| | - Manuel Bañobre-López
- Advanced (Magnetic) Theranostic Nanostructures Lab. International Iberian Nanotechnology Laboratory, Avda. Mestre José Veiga s/n, 4715-330, Braga, Portugal
| |
Collapse
|
5
|
Brito B, Price TW, Gallo J, Bañobre-López M, Stasiuk GJ. Smart magnetic resonance imaging-based theranostics for cancer. Theranostics 2021; 11:8706-8737. [PMID: 34522208 PMCID: PMC8419031 DOI: 10.7150/thno.57004] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 03/29/2021] [Indexed: 12/29/2022] Open
Abstract
Smart theranostics are dynamic platforms that integrate multiple functions, including at least imaging, therapy, and responsiveness, in a single agent. This review showcases a variety of responsive theranostic agents developed specifically for magnetic resonance imaging (MRI), due to the privileged position this non-invasive, non-ionising imaging modality continues to hold within the clinical imaging field. Different MRI smart theranostic designs have been devised in the search for more efficient cancer therapy, and improved diagnostic efficiency, through the increase of the local concentration of therapeutic effectors and MRI signal intensity in pathological tissues. This review explores novel small-molecule and nanosized MRI theranostic agents for cancer that exhibit responsiveness to endogenous (change in pH, redox environment, or enzymes) or exogenous (temperature, ultrasound, or light) stimuli. The challenges and obstacles in the design and in vivo application of responsive theranostics are also discussed to guide future research in this interdisciplinary field towards more controllable, efficient, and diagnostically relevant smart theranostics agents.
Collapse
Affiliation(s)
- Beatriz Brito
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, Strand, London, UK, SE1 7EH
- School of Life Sciences, Faculty of Health Sciences, University of Hull, Cottingham Road, Hull, UK, HU6 7RX
- Advanced Magnetic Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga, 4715-330 Braga
| | - Thomas W. Price
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, Strand, London, UK, SE1 7EH
| | - Juan Gallo
- Advanced Magnetic Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga, 4715-330 Braga
| | - Manuel Bañobre-López
- Advanced Magnetic Theranostic Nanostructures Lab, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga, 4715-330 Braga
| | - Graeme J. Stasiuk
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, Strand, London, UK, SE1 7EH
| |
Collapse
|
6
|
Starch-based magnetic nanocomposite for targeted delivery of hydrophilic bioactives as anticancer strategy. Carbohydr Polym 2021; 264:118017. [PMID: 33910740 DOI: 10.1016/j.carbpol.2021.118017] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 03/10/2021] [Accepted: 03/29/2021] [Indexed: 02/06/2023]
Abstract
Magnetic nanocomposites were synthesized for the targeted delivery of hydrophilic bioactives through guidance generated by a magnetic field. Superparamagnetic iron oxide nanoparticles (SPIONs) were used to generate hydroxyethyl starch magnetic nanocapsules (HES MNCs). This synthesis allowed the co-encapsulation of oncocalyxone A (onco A) and surface-modified magnetite nanoparticles (Fe3O4@citrate) into the same nanostructure. The synthesized nanocapsules exhibited a core-shell morphology, with an average diameter of 143 nm. This nanocomposite showed potential anticancer activity (IC50) against four human tumor cell lines: glioblastoma SNB-19 (1.010 μgmL-1), colon carcinoma HCT-116 (2.675 μgmL-1), prostate PC3 (4.868 μgmL-1), and leukemia HL-60 (2.166 μgmL-1). Additionally, in vivo toxicity and locomotor activity were evaluated in a zebrafish (Danio rerio) model. The nanocomposite exhibited in vitro cytotoxicity, prolonged drug release profile and also responded to an applied magnetic field, representing a versatile compound with perspectives for highest concentration of different hydrophilic bioactives in a target tissue through magnetic vectorization.
Collapse
|
7
|
Xyloglucan-based hybrid nanocomposite with potential for biomedical applications. Int J Biol Macromol 2020; 168:722-732. [PMID: 33232700 DOI: 10.1016/j.ijbiomac.2020.11.128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 10/19/2020] [Accepted: 11/18/2020] [Indexed: 11/23/2022]
Abstract
Natural polymer-based hybrid nanocomposites have been proposed as one of the most promising tools for biomedical applications, including disease treatment and diagnosis procedures. Xyloglucan nanocapsules can simultaneously load magnetic iron oxide nanoparticles and bioactive for a specific tissue, reducing the processes of degradation and metabolic inactivation of molecules with biological activity. In this work, magnetic nanocapsules of xyloglucan loaded with hydrophilic sulfated quercetin (MNXQ_SO3) were successfully synthesized by inverse miniemulsion process through interfacial polymerization. The polymeric shell formation of nanocapsules was evidenced by Fourier Transform Infrared spectroscopy and Transmission Electron Microscopy. The ferrofluid (Fe3O4@PAAS) incorporated into the xyloglucan nanocapsules was synthesized by hydrothermal method, using polyacrylic acid sodium salt as coating. Dynamic Light Scattering technique confirmed the nanomeric dimensions (202.3 nm) and the good colloidal stability (-40.2 mV) of MNXQ_SO3. The saturation magnetization analyses pointed out the superparamagnetic behavior of Fe3O4@PAAS (48 emu/g) and MNXQ_SO3 (4.2 emu/g). MNXQ_SO3 was able to modify the release profile of sulfated quercetin (67%) when compared to the free bioactive (100%), exhibiting a release profile compatible with the zero-order kinetic model. The results showed that the development of MNXQ_SO3 presents a new perspective for biomedical applications, including studies of targeted drug delivery.
Collapse
|
8
|
Jiménez-López J, García-Hevia L, Melguizo C, Prados J, Bañobre-López M, Gallo J. Evaluation of Novel Doxorubicin-Loaded Magnetic Wax Nanocomposite Vehicles as Cancer Combinatorial Therapy Agents. Pharmaceutics 2020; 12:E637. [PMID: 32645938 PMCID: PMC7407097 DOI: 10.3390/pharmaceutics12070637] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 06/29/2020] [Accepted: 07/02/2020] [Indexed: 01/20/2023] Open
Abstract
The development of nanotechnology-based solutions for cancer at a preclinical level advances at an astounding pace. So far, clinical translation of these new developments has not been able to keep the pace due to a range of different reasons. One of them is the mismatch between in vitro and in vivo results coming from the expected difference in complexity. To overcome this problem, extensive characterisation using advanced in vitro models can lead to stronger preliminary data to face in vivo tests. Here, a comprehensive in vitro validation of a combinatorial therapy nanoformulation against solid tumours is presented. The information extracted from the different in vitro models highlights the importance of advanced 3D models to fully understand the potential of this type of complex drugs.
Collapse
Affiliation(s)
- Julia Jiménez-López
- Institute of Biopathology and Regenerative Medicine (IBIM9090325ER), Center of Biomedical Research (CIBM), University of Granada, 18014 Granada, Spain; (J.J.-L.); (C.M.); (J.P.)
- Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18014 Granada, Spain
- Biosanitary Institute of Granada (ibs.GRANADA), University of Granada, 18014 Granada, Spain
| | - Lorena García-Hevia
- Advanced (Magnetic) Theranostic Nanostructures Lab, Health Cluster, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330 Braga, Portugal;
- The Scuola Superiore Sant’Anna, the BioRobotics Institute, Viale Rinaldo Piaggio 34, Pontedera, 56025 Pisa, Italy
| | - Consolación Melguizo
- Institute of Biopathology and Regenerative Medicine (IBIM9090325ER), Center of Biomedical Research (CIBM), University of Granada, 18014 Granada, Spain; (J.J.-L.); (C.M.); (J.P.)
- Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18014 Granada, Spain
- Biosanitary Institute of Granada (ibs.GRANADA), University of Granada, 18014 Granada, Spain
| | - Jose Prados
- Institute of Biopathology and Regenerative Medicine (IBIM9090325ER), Center of Biomedical Research (CIBM), University of Granada, 18014 Granada, Spain; (J.J.-L.); (C.M.); (J.P.)
- Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18014 Granada, Spain
- Biosanitary Institute of Granada (ibs.GRANADA), University of Granada, 18014 Granada, Spain
| | - Manuel Bañobre-López
- Advanced (Magnetic) Theranostic Nanostructures Lab, Health Cluster, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330 Braga, Portugal;
| | - Juan Gallo
- Advanced (Magnetic) Theranostic Nanostructures Lab, Health Cluster, International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330 Braga, Portugal;
| |
Collapse
|